Christopher Causey News Today

Nations Financial Group Inc. IA ADV acquired a new position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,041 shares of the biotechnology company’s stock, valued at approximately $229,000. Several other institutional […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) Director Christopher Causey sold 2,240 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares in the company, valued at […]

Jacobs Levy Equity Management Inc. lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 14.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 192,676 shares of the biotechnology company’s stock after selling 31,881 shares during the quarter. Jacobs […]

Jacobs Levy Equity Management Inc. lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 14.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 192,676 shares of the biotechnology company’s stock after selling 31,881 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in United Therapeutics were worth […]

United Therapeutics Co. (NASDAQ:UTHR – Free Report) – Analysts at Leerink Partnrs boosted their FY2027 EPS estimates for shares of United Therapeutics in a research note issued on Thursday, February 22nd. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will post earnings per share of $24.40 for the year, up from their […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) released its quarterly earnings results on Wednesday. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08, MarketWatch Earnings reports. The firm had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics […]

Covestor Ltd lowered its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 30.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 812 shares of the biotechnology company’s stock after selling 362 shares during the period. Covestor Ltd’s holdings […]

Covestor Ltd reduced its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 30.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 812 shares of the biotechnology company’s stock after selling 362 shares during the period. Covestor Ltd’s holdings in […]

Covestor Ltd lowered its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 30.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 812 shares of the biotechnology company’s stock after selling 362 shares during the period. Covestor Ltd’s holdings […]

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $300.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on the company. StockNews.com cut United Therapeutics […]